BioCryst Pharmaceuticals, Inc.
BCRXNASDAQHealthcare● Active
$8.43
+$0.02(+0.24%)
Market Cap$1.8B
P/E Ratio—
52W High$11.23
52W Low$6
BioCryst Pharmaceuticals, Inc. (BCRX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BCRX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.87B | $0.45B | $0.33B | $0.27B | $0.16B |
| Cost of Revenue | $0.02B | $0.01B | $0.00B | $0.01B | $0.01B |
| Gross Profit | $0.86B | $0.44B | $0.33B | $0.26B | $0.15B |
| Gross Margin %(computed) | 97.82% | 97.23% | 98.59% | 97.57% | 95.38% |
| Operating Expenses | |||||
| R&D Expenses | $0.17B | $0.17B | $0.22B | $0.25B | $0.21B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.51B | $0.44B | $0.43B | $0.41B | $0.33B |
| Operating Income | $0.34B | ($0.00B) | ($0.10B) | ($0.15B) | ($0.18B) |
| Operating Margin %(computed) | 38.98% | -0.56% | -31.29% | -54.81% | -113.08% |
| Interest Income | $0.01B | $0.01B | $0.02B | $0.01B | $0.00B |
| Interest Expense | $0.08B | $0.10B | $0.11B | $0.10B | $0.06B |
| Income Before Tax | $0.27B | ($0.09B) | ($0.23B) | ($0.24B) | ($0.18B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | $0.26B | ($0.09B) | ($0.23B) | ($0.25B) | ($0.18B) |
| Net Margin %(computed) | 30.16% | -19.72% | -68.36% | -91.24% | -117.11% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $1.26 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
| Wtd Avg Shares | 0.21B | 0.21B | 0.19B | 0.19B | 0.18B |
| EBITDA | $0.35B | $0.01B | ($0.12B) | ($0.14B) | ($0.12B) |
| EBITDA Margin %(computed) | 39.74% | 2.84% | -35.10% | -53.12% | -77.46% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more BioCryst Pharmaceuticals, Inc. data
About BioCryst Pharmaceuticals, Inc. (BCRX) Income Statement
BioCryst Pharmaceuticals, Inc. (BCRX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BCRX reported revenue of $0.87B, gross profit of $0.86B (gross margin 97.82%), and net income of $0.26B — a net profit margin of 30.16%.
Frequently asked questions
BCRX · 4 questionsBioCryst Pharmaceuticals, Inc. (BCRX) reported revenue of $0.87B for 2025, up 94.1% year-over-year.
BCRX revenueBCRX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08